Erratum: A replicating modified vaccinia tiantan strain expressing an avian-derived influenza h5n1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in Mice (PLoS ONE (2013) 8: 12 (e83274) DOI: 10.1371/journal.pone.0083274);A replicating Modified Vaccinia Tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Xiao, Haixia ^a,c   Liu, Li ^b   Zhu, Qingyu ^d   Tan, Zhiwu ^b   Yu, Wenbo ^b   Tang, Xian ^b   Zhan, Dawei ^d   Du, Yanhua ^b   Wang, Haibo ^b   Liu, Di ^c   Li, Zhixin ^c   Yuen, Kwok Yung ^b   Ho, David D ^e,f,g   Gao, George F ^a,c   Chen, Zhiwei ^b  

^a Chinese Academy of Sciences   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c INSTITUTE OF MICROBIOLOGY   (China)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^e GENOMICS RESEARCH CENTER   (Taiwan)

^f ROCKEFELLER UNIVERSITY   (United States)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; POXVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ARTICLE; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; EMBRYO; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION; GOOSE; H5 GENE; HEMAGGLUTINATION; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS GENE; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; CELLS, CULTURED; CHICK EMBRYO; CROSS PROTECTION; DOGS; FEMALE; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; ORGANISMS, GENETICALLY MODIFIED; ORTHOMYXOVIRIDAE INFECTIONS; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 84892924704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083274     Document Type: Erratum

References (42)

1. Webster RG, Govorkova EA (2006) H5N1 influenza-continuing evolution and spread. N Engl J Med 355: 2174-2177.
2. Webster RG, Guan Y, Poon L, Krauss S, Webby R, et al. (2005) The spread of the H5N1 bird flu epidemic in Asia in 2004. Arch Virol Suppl: 117-129.
3. Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, et al. (1998) Human influenza A H5N1 virus related to a highly pathogenic avian
4. Suarez DL, Perdue ML, Cox N, Rowe T, Bender C, et al. (1998) Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol 72: 6678-6688.
5. Xu X, Subbarao, Cox NJ, Guo Y (1999) Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 261: 15-19.
6. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2013. WHO website. Available: http://www.who.int/ influenza/human-animal-interface/EN-GIP-20130705CumulativeNumber-H5N1cases-2. pdf Accessed 05 July 2013.
7. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, et al. (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420-428.
8. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, et al. (2012) Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336: 1534-1541.
9. Russell CA, Fonville JM, Brown AE, Burke DF, Smith DL, et al. (2012) The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 336: 1541-1547.
10. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, et al. (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A 105: 13538-13543.
11. Steel J (2011) New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 25: 285-298.
12. Minor PD (2010) Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 50: 560-565.
13. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367: 475-481.
14. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80: 1959-1964.
15. Vajo Z, Kosa L, Szilvasy I, Pauliny Z, Bartha K, et al. (2008) Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr Infect Dis J 27: 1052-1056.
16. Steel J, Lowen AC, Pena L, Angel M, Solorzano A, et al. (2009) Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 83: 1742-1753.
17. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, et al. (2008) Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3: e1401.
18. Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, et al. (2011) Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PloS one 6: e16247.
19. Ge J, Deng G, Wen Z, Tian G, Wang Y, et al. (2007) Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol 81: 150-158.
20. Yu W, Fang Q, Zhu W, Wang H, Tien P, et al. (2010) One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge. Vaccine 28: 2088-2096.
21. Q. Jin LHC, S.X Chen, J Huang, Z.H Feng, J.S Yuan, D.Y Jin, H.D Bai and Y.D Hou (1977) Characterization of the complete genomic sequence of the vaccinia virus Tian Tan strain. Sci China 27: 562-567.
22. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, et al. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/ Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937-1943.
23. Zhu JH, Wang J, Cai B, Zhao W, Zhu Y, et al. (1996) Immunogenicity and relative attenuation of different vaccinia-rabies virus recombinants. Arch Virol 141: 1055-1065.
24. Huang X, Lu B, Yu W, Fang Q, Liu L, et al. (2009) A novel replicationcompetent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS ONE 4: e4180.
25. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, et al. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 96: 9345-9350.
26. Chen Z, Zhang L, Qin C, Ba L, Yi CE, et al. (2005) Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 79: 2678-2688.
27. Morgan DJ, Kurts C, Kreuwel HT, Holst KL, Heath WR, et al. (1999) Ontogeny of T cell tolerance to peripherally expressed antigens. Proc Natl Acad Sci U S A 96: 3854-3858.
28. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, et al. (1999) A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73: 5903-5911.
29. Reid AH, Taubenberger JK (2003) The origin of the 1918 pandemic influenza virus: a continuing enigma. J Gen Virol 84: 2285-2292.
30. Olson DR, Simonsen L, Edelson PJ, Morse SS (2005) Epidemiological evidence of an early wave of the 1918 influenza pandemic in New York City. Proc Natl Acad Sci U S A 102: 11059-11063.
31. Globig A, Staubach C, Beer M, Koppen U, Fiedler W, et al. (2009) Epidemiological and ornithological aspects of outbreaks of highly pathogenic avian influenza virus H5N1 of Asian lineage in wild birds in Germany, 2006 and 2007. Transbound Emerg Dis 56: 57-72.
32. Shu Y, Yu H, Li D (2006) Lethal avian influenza A (H5N1) infection in a pregnant woman in Anhui Province, China. N Engl J Med 354: 1421-1422.
33. Yu H, Shu Y, Hu S, Zhang H, Gao Z, et al. (2006) The first confirmed human case of avian influenza A (H5N1) in Mainland China. Lancet 367: 84.
34. Zhu W, Fang Q, Zhuang K, Wang H, Yu W, et al. (2007) The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. J Virol Methods 144: 17-26.
35. Fang Q, Yang L, Zhu W, Liu L, Wang H, et al. (2005) Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology 335: 242-251.
36. Barouch DH, Santra S, Kuroda MJ, Schmitz JE, Plishka R, et al. (2001) Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 75: 5151-5158.
37. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B (1994) A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12: 1032-1040.
38. Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, et al. (1997) Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15: 387-394.
39. Hanke T, Blanchard TJ, Schneider J, Ogg GS, Tan R, et al. (1998) Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J Gen Virol 79 (Pt 1): 83-90.
40. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, et al. (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4: 397-402.
41. Seth A, Ourmanov I, Kuroda MJ, Schmitz JE, Carroll MW, et al. (1998) Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proc Natl Acad Sci U S A 95: 10112-10116.
42. Liu J, Xiao H, Lei F, Zhu Q, Qin K, et al. (2005) Highly pathogenic H5N1 influenza virus infection in migratory birds. Science 309: 1206.